asfotase alfa clinical trials

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

This study is looking at a new medicine called ALXN1850 for children with a rare bone condition called hypophosphatasia (HPP). It compares ALXN1850 with a current treatment, asfotase alfa, to see if it's safe and works well for children who have already been using asfotase alfa.